Curcumin III makes Curcumin BDM30™ the new standard
Updated: Jun 21, 2021
by Franco Cavaleri BSc PhDc (Exper Medicine)
Original post: August 3, 2017
Curcumin BDM30™ is not regular curcumin. Curcumin BDM30™ is based on a recent research discovery that changes what we know about curcumin and how we can use it to deliver therapeutic relief. The discovery made at Biologic Pharmamamedical Research by Franco Cavaleri PhDc has recently been granted full patent status after a lengthy review; and NPN status for approved sales/safety and validation of researched claims. How is it different? Curcumin is typically comprised of three main curcuminoids. Every curcumin extract product supplies all three curcuminoids in a ratio similar to: curcumin I (70-80%); curcumin II (12-20%); curcumin III (0.5-1.5%). The latest discovery made by Franco Cavaleri, PhDc, the principal research scientist at Biologic Pharmamedical (www.biologicpharmamedical.com) , and the Chief Science Officer at Rhema Health Products, shows for the first time that curcumin III and not curcumins I or II inhibits (helps control) MSK1.
MSK1 is a regulatory protein that regulates production (transactivation) of inflammatory chemicals at a genomic level. By turning this MSK1 level down the, cells – the body – are better able to control inflammation from a second pathway that is additive to the one regular basic curcumin helps control. Curcumin III does everything the other curcuminoids do plus it helps regulate MSK1 for incremental anti-inflammatory support from a second control point.
This same research shows that regular curcumin extract (even the 95%) does not affect MSK1 in any positive way. Curcumin III levels are simply not high enough for functionality in regular curcumin. The new Curcumin BDM30™ is a new standard of anti-inflammatory offering 60x more BDMC (curcumin III) than regular curcumin, providing immense joint pain relief and more rapid recovery from inflammation caused from injuries and exercise.
Conflict of Interest Statement. The author/researcher is the owner of a biomedical research group – Biologic Nutrigenomics Health Research Corp and Biologic Pharmamedical Research, that funds and executes research on the pharmacology of nutritional and nutraceutical agents that are studied in the context of disease pathology including characteristics that have been associated with inflammation and dementias. The research on these findings continues at clinical levels to further investigate the full indication-specific potential of this discovery. The author/researcher is also the owner of related Intellectual Properties. author copyright Franco Cavaleri PhDc
Franco Cavaleri, BSc, PhDc, is The Rhema Group’s Chief Science Officer. He is also the principal research scientist at Biologic Pharmamedical; is a former Mr. IFBB North America; and is completing a doctoral degree in Experimental Medicine in the Faculty of Medicine.